US EditionCARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
SHANGHAI, CHINA, JUN 2 – Satri-cel showed significant improvement in survival and tumor response for advanced gastric cancer patients after two prior therapies, gaining breakthrough designations in China and the U.S.
- CARsgen Therapeutics announced on June 1, 2025, the Phase II trial results of satricabtagene autoleucel for advanced gastric/gastroesophageal junction cancer in China.
- The trial was a randomized controlled study involving patients with Claudin18.2-positive tumors who had not responded to a minimum of two previous treatment regimens.
- The results demonstrating satri-cel's significant improvements in progression-free survival, overall survival, and tumor response rates were published in The Lancet and featured through an oral presentation during the 2025 ASCO Annual Meeting.
- Founder Zonghai Li stated that the successful outcome of this randomized controlled study represents a significant advancement in the treatment of solid tumors using CAR-T therapy.
- CARsgen intends to file regulatory approval documents with China's NMPA this month for satri-cel, aiming for it to become the first CAR-T therapy approved for treating solid tumors.
97 Articles
97 Articles
Bennington Banner
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
SHANGHAI, June 1, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel…
CARsgen showcases Satri-cel breakthroughs at ASCO 2025 and in The Lancet
SHANGHAI, June 2, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel ("satri-cel", CT041) (a Claudin18.2-specific autologous CAR T-cell product candidate) in patients with Claudin18.2-positive, advanced gastric/…
Coverage Details
Bias Distribution
- 66% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
